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Reply
Regarding Becquemin et al’s letter criticizing our article about
endovascular aneurysm repair (EVAR) in France, we wish to clarify
two points and then respond to several specific comments. The first
clarification involves the conclusion of the study. We did not, as
stated in the letter, conclude that “EVAR is not in compliance with
the French rules.” We found that EVAR had not been properly
evaluated in France and that potentially valuable data had been
lost. The second point requiring clarification involves the charge
that the physicians involved were not informed of the conclusions
of our study. In fact, a more exhaustive report was published and
sent to all French vascular surgeons and relevant scientific societies
in October 2002. It is interesting to note that this information
caused less reaction when presented in French within a strictly
national context than in English in a major international journal.
Becquemin et al wrote that the French National Health Insur-
ance Fund for Salaried Workers (CNAMTS, French acronym)
cannot be considered as “independent of administrative, commer-
cial, or political interests.” Here a little background might be
useful. The CNAMTS covers 80% of the French population, with
an estimated global budget of US$ 171 billion for 2004. Since all
decisions concerning health care coverage are taken by the govern-
ment, the CNAMTS has no administrative or political conflicts of
interest. Nor can any commercial bias be suspected since, unlike
many health care professionals, CNAMTS personnel are not solic-
ited by industry to promote products.
The letter also stated that “the medical advisors of the
CNAMTS have no training in clinical research and were rarely
familiar with vascular diseases.” This statement aimed at discredit-
ing the physicians of the CNAMTS is unfair and untrue. CNAMTS
medical advisors are trained to investigate medical practices using
precisely defined techniques suited to the topic of inquiry. The data
of this study were obtained by consulting medical charts. Since this
study was not performed for legal purposes, there was no cross-
examination procedure. However, results were communicated
back to the practitioners through reports made by regional repre-
sentatives of the CNAMTS medical service.
The treatment standards used by CNAMTS medical advisors
were not contested by any practitioners. The most important
standard was aneurysm diameter. In this regard it should be
pointed out that Becquemin et al’s letter contains two important
chronological errors. First, the ANAES report1 was published in
June 1999 before the beginning of the CNAMTS investigation
and specifically recommended treatment for aneurysms greater
than 5 cm and surveillance for smaller aneurysms. The second
chronological error involves the date of publication of the United
Kingdom Small Aneurysm Trial2, which was 1998 and not 2002.
In June 1999 it is unlikely that any French practitioner was
unaware of the recommended cutoff for surveillance and treat-
ment. Yet 30% of EVAR procedures performed in France from
June 1999 to May 2001 involved aneurysms smaller than 5 cm.
This percentage would not change significantly if the few cases
involving isolated iliac aneurysm were withdrawn.
As Becquemin et al pointed out, our study did not include a
control group or compare mortality and morbidity after surgeryand EVAR. Our response to this critique is twofold. First, the
purpose of the study was not to compare EVAR and surgery, but to
know if EVAR had been evaluated properly. Second, it is well
known that most comparative studies on this point are biased
because the criteria of selection for EVAR are not the same as those
for “surgical” patients.
Becquemin et al fault us for not recognizing the Eurostar
register. They claim that the recommendations for the creation of
a national register were not issued before 2002 and that in the
meantime many patients treated in France between 1999 and 2001
were included in the Eurostar register. This critique overlooks the
fact that in 1999 a follow-up register was considered mandatory by
the ANAES and by the French Society for Vascular Surgery. In
fact, despite these recommendations only 192 of the stent grafts
placed in France before 2001 were reported in the Eurostar regis-
ter.3
The suggestion that the CNAMTS is trying to block the
development of new technologies in France is again unfair and
untrue. The CNAMTS covers the total expenditures of French
university hospitals including 13% devoted to teaching and re-
search. Specifically regarding EVAR, the CNAMTS has been cov-
ering procedures performed in the framework of trials since 1999.
In fact, the CNAMTS has simply applied French Law for clinical
research and specific decisions of the Health Ministry concerning
EVAR. A major factor in the adverse decisions taken by the Health
Ministry has been the negative effect that the undisciplined behav-
ior of French practitioners has had on administrative and political
officials.
In conclusion, it might be well to open this French debate up
to an international context. As Frank Veith wrote in his invited
commentary about our article, “it is likely that physician and
surgeon behavior is not going to differ greatly in the rest of the
world.” The ASERNIP-S report4 made for the Australian Govern-
ment Department of Health and Aging supports this view by
showing that 14.2% of patients who underwent EVAR did not
undergo adequate follow-up and that 27.2% had aneurysms with
an initial diameter less than or equal to 5 cm. These findings are
quite similar to ours.
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